In vivo validation of 3′deoxy-3′-[18F]fluorothymidine ([18F]FLT) as a proliferation imaging tracer in humans: Correlation of [18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3315-3323

  Vesselle, Hubert ^a   Grierson, John ^a   Muzi, Mark ^a   Pugsley, Jeffrey M ^a   Schmidt, Rodney A ^b   Rabinowitz, Peter ^b   Peterson, Lanell M ^a   Valliéres, Eric ^b   Wood, Douglas E ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; 3' FLUOROTHYMIDINE F 18; KI 67 ANTIGEN; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; FLUORESCENT DYE; FLUORINE;

ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; TUMOR BIOPSY; VALIDATION PROCESS; BIOSYNTHESIS; CELL DIVISION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LUNG TUMOR; METHODOLOGY; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; DIDEOXYNUCLEOSIDES; FLOW CYTOMETRY; FLUORESCENT DYES; FLUORINE RADIOISOTOPES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036847428     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Harpole, D. J., Herndon, J. E., II, Wolfe, W. G., Inglehart, J. D., and Marks, J. R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res., 55: 51-56, 1995
2. 0 non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg., 106: 80-89, 1993
3. Takise, A., Kodama, T., Shimosato, Y., Watanabe, S., and Suemasu, K. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer (Phila.), 61: 2083-2088, 1988
4. Dazzi, H., Thacher, N., Hasleton, P., Chatterjee, A., and Lawson, R. DNA analysis by flow cytometry in nonsmall cell lung cancer: Relationship to epidermal growth factor receptor, histology, tumour stage and survival. Respir. Med., 84: 217-223, 1990
5. Filderman, A., Silvestri, G., Gatsonis, C., Luthringer, D., Honig, J., and Flynn, S. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer. Am. Rev. Respir. Dis., 146: 707-710, 1992
6. tenVelde, G., Schutte, B., Vermeulen, A., Volovics, A., Reynders, M., and Blijham, G. Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer. Eur. J. Cancer Clin. Oncol., 24: 455-460, 1988
7. Volm, M., Hahn, E., Mattern, J., Muller, T., Vogt-Moykopf, I., and Weber, E. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res., 48: 2923-2928, 1988
8. Ishida, T., Kaneko, S., Akazawa, K., Tateishi, M., Sugio, K., and Sugimachi, K. Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients. Cancer Res., 53: 5000-5003. 1988
9. Ebina, M., Steinberg, S., Mulshine, J., and Linnoila, R. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res., 54: 2496-2503, 1988
10. Fontanini, G., Macchiarini, P., Pepe, S., Ruggiero, A., Hardin, M., Bigini, D., Vignati, S., Pingitore, R., and Angeletti, C. A. The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. Cancer (Phila.), 70: 1520-1527, 1992
11. Macchiarini, P., Fontanini, G., Hardin, M., Squartini, F., and Angeletti, C. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet, 340: 145-146, 1992
12. Hommura, F., Dosaka-Akita, H., Mishina, T., Nishi, M., Kojima, T., Hiroumi, H., Ogura, S., Shimizu, M., Katoh, H., and Kawakami, Y. Prognostic significance of p27KIPprotein and ki-67 growth fraction in non-small cell lung cancers. Clin. Cancer Res., 6: 4073-4081, 2000
13. 1 non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 40: 787-796, 1998
14. Puglisi, F., Aprile, G., Bruckbauer, M., Barbone, F., Damante, G., Guerra, S., Beltrami, C. A., and Di Loreto, C. Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas. Cancer Lett., 162: 97-103, 2001
15. Mehdi, S., Etzell, J., Newman, N., Weidner, N., Kohman, L., and Graziano, S. Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung Cancer, 20: 99-108, 1998
16. Pence, J., Kerns, B., Dodge, R., and Igelhart, J. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch. Surg., 128: 1382-1390, 1993
17. Shiba, M., Kohno, H., Kakizawa, K., Iizasa, T., Otsuji, M., Saitoh, Y., Hiroshima, K., Ohwada, H., and Fujisawa, T. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer (Phila.), 89: 1457-1465, 2000
18. 11C]thymidine imaging of malignant brain tumors. Cancer Res., 59: 615-621, 1999
19. Mankoff, D. A., Shields, A. F., Graham, M. M., Link, J. M., Eary, J. F., and Krohn, K. A. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: Compartmental model and mathematical analysis. J. Nucl. Med., 39: 1043-1055, 1998
20. 11C]thymidine PET imaging studies: Validation studies. J. Nucl. Med., 40: 614-624, 1999
21. Martiat, P., Ferrant, A., Labar, D., Cogneau, M., Bol, A., Michel, C., Michaux, J. L., and Sokal, G. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J. Nucl. Med., 29: 1633-1637, 1988
22. Shields, A. F., Mankoff, D. A., Link, J. M., Graham, M. M., Eary, J. F., Kozawa, S. M., Zheng, M., Lewellen, B., Lewellen, T. K., Grierson, J. R., and Krohn, K. A. Carbon-11-thymidine and FDG to measure therapy response. J. Nucl. Med., 39: 1757-1762, 1998
23. 11C-thymidine activity in human head and neck tumours using positron emission tomography (PET). Acta Oncol., 31: 539-543, 1992
24. Young, H., Brock, C., Wells, P., and Price, P. Monitoring response to treatment in the development of anti-cancer drugs using positron emission tomography. Drug Inf. J., 33: 237, 1999
25. Conti, P. S., Alauddin, M. M., Fissekis, J. R., Schmall, B., and Watanabe, K. A. Synthesis of 2′-fluoro-5-[11C]-methyl-β-D-arabinofuranosyluracil ([11C]-FMAU): A potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl. Med. Biol., 22: 783-789, 1995
26. Bading, J. R., Shahinian, A. H., Bathija, P., and Conti, P. S. Pharmacokinetics of the thymidine analog 2′-fluoro-5-[14C]-methyl-1-β-D-arabinofuranosyluracil ([14C]-FMAU) in rat prostate tumor cells. Nucl. Med. Biol., 27: 361-368, 2000
27. Tjuvajev, J., Muraki, A., Ginos, J., Berk, J., Koutcher, J., Ballon, D., Beattie, B., Finn, R., Dahighian, F., and Blasberg, R. Iododeoxyuridine uptake and retention as a measure of tumor growth [published erratum appears in J. Nucl. Med., 34: 1645, 1993]. J. Nucl. Med., 34: 1152-1162, 1993
28. 124I]iododeoxyuridine. Cancer Res., 60: 624-635, 2000
29. Grierson, J. R., and Shields, A. F. Radiosynthesis of 3′-deoxy-3′-[F-18]fluorothymidine: [F-18]FLT for imaging cellular proliferation in vivo. Nucl. Med. Biol., 27: 143-156, 2000
30. Grierson, J. R., Vesselle, H., Hofstrand, P., Chin, L., and Rasey, J. Comparative uptake and cell cycle measurements with [F-18]FLT vs [H-3]thymidine in mammalian tumor cells. J. Nucl. Med., 39: 229, 1998
31. Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H-J., Stayanoff, J. C., Lawhorn-Crews, J. M., Obradovich, J., Muzik, O., and Mangner, T. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med., 4: 1334-1336, 1998
32. Rasey, J. S., and Grierson, J. R. 3′-deoxy-3′-[F-18] fluorothymidine predicts changes in cell proliferation. J. Nucl. Med. 40: 25, 1999
33. Rasey, J. S., Grierson, J. R., Wiens, L. W., and Kolb, P. E. Uptake of labeled FLT correlates with thymidine kinase (TKI) activity in human tumor cells. J. Nucl. Med., 41: 36, 2000
34. Schwartz, J. L., Grierson, J. R., Rasey, J. S., Wiens, L., Jordan, R., and Kohli, T. Rates of accumulation and retention of 3′-deoxy-3′-fluorothymidine (FLT) in different cell lines. J. Nucl. Med., 42: 283, 2001
35. Arner, E. S., Spasokoukotskaja, T., and Eriksson, S. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem. Biophys. Res. Commun., 188: 712-718, 1992
36. Langen, P., Etzold, G., Hintsche, R., and Kowollick, G. 3′-deoxy-3′-fluorothymidine, a new selective inhibitor of DNA synthesis. Acta. Biol. Med. Ger., 23: 759-766, 1969
37. Matthes, E., Lehmann, C., Scholz, D., Rosenthal, H-A., and Langen, P. Phosphorylation, anti-HIV activity and cytotoxicity of 3′-fluorothymidine. Biochem. Biophys. Res. Commun., 153: 825-831, 1988
38. Munch-Petersen, B., Cloos, L., Tyrsted, G., and Eriksson, S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J. Biol. Chem., 266: 9032-9038, 1991
39. Sherley, J. L., and Kelly, T. J. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem., 263: 8350-8358, 1988
40. Sundseth, R., Joyner, S. S., Moore, J. T., Dornsife, R. E., and Dev, I. K. The anti-human immunodeficiency virus agent 3′-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells. Antimicrob. Agents Chemother., 40: 331-335, 1996
41. 18F-Fluorothymidine PET imaging of non-small cell lung cancer (NSCLC): Comparison to Ki-67 proliferation index. J. Nucl. Med., 42: 29, 2001
42. Graham, M. M., and Lewellen, B. L. High-speed automated discrete blood sampling for positron emission tomography. J. Nucl. Med., 34: 1357-1360, 1993
43. Kohlmyer, S., Vesselle, H., Miyaoka, R., Kaplan, M., and Lewellen, T. Comparison of recovery coefficients for PET based on maximum and average ROI pixel values. Presented at the 2000 European Association of Nuclear Medicine Congress. Paris, Sept. 2-6, 2000
44. Vesselle, H., Schmidt, R. A., Pugsley, J. M., Li, M., Kohlmyer, S. G., Valliéres, E., and Wood, D. E. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin. Cancer Res, 6: 3837-3844, 2000
45. Patlak, C., Blasberg, R., and Fenstermacher, J. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab., 3: 1-7, 1983
46. Key, G., Becker, M. H., Baron, B. Duchrow, M., Schluter, C., Flad, H. D., and Gerdes, J. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Investig., 68: 629-636, 1993
47. Shields, A. F., Dohmen, B. M., Grierson, J. R., Kuntzsch, M., Machulla, H-J., and Bares, R. Imaging with [F-18]FLT and FDG in patients with cancer. J. Nucl. Med., 40: 61, 1999
48. Shields, A. F., Dohmen, B. M., Mangner, T. J., Lawhorn-Crews, J. M., Machulla, H., Muzik, O., and Bares, R. Imaging of thoracic tumors with [F-18]FLT. J. Nucl. Med., 41: 74, 2000
49. 18FFLT for breast cancer Imaging. J. Nucl. Med., 42: 29, 2001
50. 18F-FLT for imaging gastrointestinal tumors. J. Nucl. Med., 42: 29, 2001
51. Schwarting, R. Little missed markers and Ki-67. Lab. Invest., 68: 597-599, 1993
52. McCormick, D., and Hall, P. The complexities of proliferating cell nuclear antigen. Histopathology, 21: 591-594, 1992
53. Hall, P., Levinson, D., Woods, A. L., Yu, C. C., Kellock, D. B., Watkins, J. A., Barres, D. M., Gillett, C. E., Camplejohn, R., and Dover, R. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms., J., Pathol., 162: 285-294, 1990
54. Gerdes, J., Lemke, H., Baisch, H., Wacker, H., Schwab, U., and Stein, H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67., J., Immunol., 133: 1710-1715, 1984
55. Schluter, C., Duchrow, M., Wohlenberg, C., Becker, M. H., Key, G., Flad, H. D., and Gerdes, J. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J. Cell Biol., 123: 5 13-522, 1993
56. Scholzen, T., and Gerdes, J. The Ki-67 protein: From the known and the unknown. J. Cell Physiol., 182: 311-322, 2000
57. Rudolph, P., Peters, J., Lorenz, D., Schmidt, D., and Parwaresch, R. Correlation between mitotic and Ki-67 labeling indices in paraffin-embedded carcinoma specimens. Hum. Pathol., 29: 1216-1222, 1998
58. Cattoretti, G., Becker, M., Key, G., Duchrow, M., Schluter, C., Galle, J., and Gerdes, J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol., 168: 357-363, 1992
59. Toyohara, J., Kato-Azuma, M., Waki, A., Takamatsu, S., Yonekura, Y., Magata, Y., and Fujibayashi, Y. Basis of FLT as a cell proliferation marker: Comparative uptake studies with thymidine, arabinothymidine and FDG, and cell-analysis in 22 asynchronously growing tumor cell lines. J. Nucl. Med., 42: 83, 2001
60. Arner, E. S. J., and Eriksson, S. Mammalian deoxyribonucleoside kinases. Pharmacol. Ther., 67: 155-186, 1995